Literature DB >> 26928042

Expression of vascular endothelial growth factor (VEGF)-B and its receptor (VEGFR1) in murine heart, lung and kidney.

Lars Muhl1, Christine Moessinger1, Milena Z Adzemovic1, Marike H Dijkstra2, Ingrid Nilsson1, Manuel Zeitelhofer1, Carolina E Hagberg1,3, Jenni Huusko2, Annelie Falkevall1, Seppo Ylä-Herttuala2, Ulf Eriksson4.   

Abstract

Metabolic diseases, such as obesity and diabetes, are a serious burden for the health system. Vascular endothelial growth factor (VEGF)-B has been shown to regulate tissue uptake and accumulation of fatty acids and is thus involved in these metabolic diseases. However, the cell-type-specific expression pattern of Vegfb and its receptor (VEGFR1, gene Flt1) remains unclear. We explore the expression of Vegfb and Flt1 in the murine heart, lung and kidney by utilizing β-galactosidase knock-in mouse models and combining the analysis of reporter gene expression and immunofluorescence microscopy. Furthermore, Flt1 heterozygous mice were analyzed with regard to muscular fatty acid accumulation and peripheral insulin sensitivity. Throughout the heart, Vegfb expression was found in cardiomyocytes with a postnatal ventricular shift corresponding to known changes in energy requirements. Vegfb expression was also found in the pulmonary myocardium of the lung and in renal epithelial cells of the thick ascending limb of Henle's loop, the connecting tubule and the collecting duct. In all analyzed organs, VEGFR1 expression was restricted to endothelial cells. We also show that reduced expression of VEGFR1 resulted in decreased cardiac fatty acid accumulation and increased peripheral insulin sensitivity, possibly as a result of attenuated VEGF-B/VEGFR1 signaling. Our data therefore support a tightly controlled, paracrine signaling mechanism of VEGF-B to VEGFR1. The identified cell-specific expression pattern of Vegfb and Flt1 might form the basis for the development of cell-type-targeted research models and contributes to the understanding of the physiological and pathological role of VEGF-B/VEGFR1 signaling.

Entities:  

Keywords:  Endothelial cells; Gene expression pattern; Insulin sensitivity; VEGF-B; VEGFR1

Mesh:

Substances:

Year:  2016        PMID: 26928042     DOI: 10.1007/s00441-016-2377-y

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  15 in total

1.  Resveratrol alleviates sepsis-induced acute lung injury by suppressing inflammation and apoptosis of alveolar macrophage cells.

Authors:  Lei Yang; Zhen Zhang; Yuzhen Zhuo; Lihua Cui; Caixia Li; Dihua Li; Shukun Zhang; Naiqiang Cui; Ximo Wang; Hongwei Gao
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

2.  Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study.

Authors:  Sara García-Serrano; Eva García-Escobar; Ana Lago-Sampedro; Said Lhamyani; Sergio Valdés; Natalia Colomo; Cristina Maldonado-Araque; Inmaculada González-Molero; Viyey Doulatram-Gamgaram; Elias Delgado; Felipe J Chaves; Luis Castaño; Alfonso Calle-Pascual; Josep Franch-Nadal; Gemma Rojo-Martínez
Journal:  Int J Obes (Lond)       Date:  2022-08-20       Impact factor: 5.551

Review 3.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

Review 4.  The role of vascular endothelial growth factor-B in metabolic homoeostasis: current evidence.

Authors:  Mohammad Ishraq Zafar; Juan Zheng; Wen Kong; Xiaofeng Ye; Luoning Gou; Anita Regmi; Lu-Lu Chen
Journal:  Biosci Rep       Date:  2017-08-30       Impact factor: 3.840

Review 5.  Antiangiogenic Therapy for Diabetic Nephropathy.

Authors:  Katsuyuki Tanabe; Yohei Maeshima; Yasufumi Sato; Jun Wada
Journal:  Biomed Res Int       Date:  2017-08-01       Impact factor: 3.411

6.  An update on diabetic kidney disease, oxidative stress and antioxidant agents.

Authors:  Leila Mahmoodnia; Esmat Aghadavod; Sara Beigrezaei; Mahmoud Rafieian-Kopaei
Journal:  J Renal Inj Prev       Date:  2017-01-20

Review 7.  Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons.

Authors:  Beatrice Caballero; Scott J Sherman; Torsten Falk
Journal:  Parkinsons Dis       Date:  2017-04-03

8.  Vascular Endothelial Growth Factor B and Its Signaling.

Authors:  Nathaniel Lal; Karanjit Puri; Brian Rodrigues
Journal:  Front Cardiovasc Med       Date:  2018-04-20

9.  VEGF-B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content.

Authors:  Christine Moessinger; Ingrid Nilsson; Lars Muhl; Manuel Zeitelhofer; Benjamin Heller Sahlgren; Josefin Skogsberg; Ulf Eriksson
Journal:  EMBO Rep       Date:  2020-05-24       Impact factor: 8.807

Review 10.  Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.

Authors:  Rhian M Touyz; Joerg Herrmann
Journal:  NPJ Precis Oncol       Date:  2018-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.